Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 8;9(10):1145.
doi: 10.3390/vaccines9101145.

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

Dong-Ho Jo  1 , Dohsik Minn  2 , Jaegyun Lim  3 , Ki-Deok Lee  1 , Yu-Min Kang  1 , Kang-Won Choe  1 , Kwang-Nam Kim  4
Affiliations

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

Dong-Ho Jo et al. Vaccines (Basel). .

Abstract

The efficacy and safety of the BNT162b2 vaccine are known, but antibodies are expected to decrease over time after vaccination. We collected blood samples from 104 fully vaccinated health care workers at 3 and 5 weeks after first vaccination and 4 months after second vaccination. Antibody titers and neutralizing antibodies were measured. In our study, both antibody titers and neutralizing antibodies increased significantly at 5 weeks after first vaccination but decreased rapidly at 4 months after second vaccination. Additionally, the results showed a significant decrease regardless of gender or age. Further studies are needed to help determine the interval of SARS-CoV-2 vaccinations.

Keywords: BNT162 vaccine; SARS-CoV-2; antibodies; neutralizing antibodies; vaccine immunogenicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor binding domain (RBD) counts. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. (b) Neutralizing antibodies counts. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.
Figure 2
Figure 2
(a) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by gender. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. (b) Neutralizing antibodies counts by gender. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.
Figure 3
Figure 3
(a) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by age. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. (b) NeuTable 3 and 5 weeks after first vaccination and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.
See this image and copyright information in PMC

References

    1. WHO Coronavirus (COVID-19) Dashboard. [(accessed on 1 October 2021)]. Available online: https://covid19.who.int/
    1. Chung Y.H., Beiss V., Fiering S.N., Steinmetz N.F. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano. 2020;14:12522–12537. doi: 10.1021/acsnano.0c07197. - DOI - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Walsh E.E., Frenck R.W., Jr., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439–2450. doi: 10.1056/NEJMoa2027906. - DOI - PMC - PubMed
    1. Korea Centers for Disease and Prevention. [(accessed on 1 October 2021)]; Available online: http://www.kcdca.go.kr/

LinkOut - more resources